ATX-201 Uses, Dosage, Side Effects and more
ATX-201 is one of a family of novel compounds that inhibits microtubule polymerization. It is developed by Kythera Biopharmaceuticals, Inc. for the treatment of actinickeratosis. The company announced the decision to discontinue its ATX-201 clinical program for actinic keratosis. The Company determined that the program was not meeting their expected primary and exploratory objectives.
| Attribute | Details |
|---|---|
| Trade Name | ATX-201 |
| Generic | ATX-201 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in actinic keratosis.
